ACC 2015: Edwards, Medtronic lock horns with positive next-gen TAVI data
This article was originally published in Clinica
The rivalry between the two leading firms in the transcatheter aortic valve implantation (TAVI) market, Edwards Lifesciences and Medtronic, looks set to continue, with both reporting positive results with their next-generation devices. The data were presented at the American College of Cardiology (ACC) meeting, being held in San Diego, California on 14-16 March.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.